EMA gives the green light to the first adrenaline nasal spray for the urgent treatment of allergic reactions
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation in the European Union for Eurneffy (epinephrine), the first nasally administered medicine for the emergency treatment of allergic reactions. Anaphylaxis is the most severe form of allergic reaction that can occur within minutes of exposure to an allergen and can be life-threatening. Until now, treatment with epinephrine (also known as adrenaline) to reduce the anaphylactic reaction is done by intramuscular injection.
0